Drug-Related Hospital Visits and Admissions Associated with Laboratory or Physiologic Abnormalities—A Systematic-Review

Kerry Wilbur*, Huda Hazi, Aya El-Bedawi

College of Pharmacy, Qatar University, Doha, Qatar

Abstract

Countless studies have demonstrated that many emergency-room visits and hospital admissions are drug-related and that a significant proportion of these drug-related visits (DRVs) are preventable. It has not been previously studied which DRVs could be prevented through enhanced monitoring of therapy. The objective of the study was to determine the incidence of DRVs attributed to laboratory or physiologic abnormalities. Three authors independently performed comprehensive searches in relevant health care databases using pre-determined search terms. Articles discussing DRV associated with poisoning, substance abuse, or studied among existing in-patient populations were excluded. Study country, year, sample, design, duration, DRV identification method, proportion of DRVs associated with laboratory or physiologic abnormalities and associated medications were extracted. The three authors independently assessed relevant studies according to the Strengthening the reporting of observational studies in epidemiology (STROBE) as applicable according to the studies’ methodology. The initial literature search yielded a total of 1,524 articles of which 30 articles meeting inclusion criteria and reporting sufficient laboratory or physiologic data were included in the overall analysis. Half employed prospective methodologies, which included both chart review and patient interview; however, the overwhelming majority of identified studies assessed only adverse drug reactions (ADRs) as a drug-related cause for DRV. The mean (range) prevalence of DRVs found in all studies was 15.4% (0.44%–66.7%) of which an association with laboratory or physiologic abnormalities could be attributed to a mean (range) of 29.4% (4.3%–78.1%) of cases. Most laboratory-associated DRVs could be linked to immunosuppressant, antineoplastic, anticoagulant and diabetes therapy, while physiologic-associated DRVs were attributed to cardiovascular therapies and NSAIDs. Significant proportions of laboratory and physiologic abnormalities contribute to DRVs and are consistently linked to specific drugs. These therapies are potential targets for enhanced medication monitoring initiatives to proactively avert potential DRVs.

Introduction

Drug-related emergency room visits and hospital admissions (DRVs) are a significant contributor to morbidity, mortality and health care costs worldwide. While most documentation of the problem has focused on DRVs attributed to adverse drug reactions (ADRs), few researchers have explored other drug-related problem (DRP) etiologies categorized within the pharmaceutical care nosology, including inappropriate medication selection or dosing; untreated symptoms or disease; drug interactions; and patient non-adherence [1–5]. Features of patient populations at-risk for DRVs have been consistently described (the elderly, those with impaired cognition, dependent living situations, renal insufficiency, multiple comorbidities or polypharmacy) as have the most common offending therapies (antiplatelets, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDS), diuretics, angiotensin converting enzyme (ACE) inhibitors, opioids, and diabetes treatments) [6–8].

Several broad recommendations for the reduction of preventable DRVs have been proposed such as improving communication between acute and ambulatory health care providers when patients transition between care settings; conducting regular review of prescription medications to avoid therapeutic duplication and to discontinue unnecessary drugs; advising patients to frequented one community pharmacy and to discuss self-selection of over-the-counter (OTC) and herbal therapy with a pharmacist or physician [9–11]. Enhanced patient monitoring is also frequently suggested. Baseline and follow-up assessment of renal function in populations at-risk is most often cited, but improving the monitoring of other specific laboratory values according to the prescribed therapy (e.g. INR for anticoagulated patients, potassium for diuretic-treated patients) is also advocated. Unfortunately, low adherence to enhanced laboratory monitoring has been demonstrated even when straightforward protocols are devised [12–14]. Early detection of DRPs does not always require blood testing; certain unfavourable medication responses manifesting clinically may be recognized by straightforward patient assessment. Simple vital sign evaluation is efficient and non-invasive and therefore has potential for greater drug monitoring adherence. Altered body physiology leading to harmful conditions and

Citation: Wilbur K, Hazi H, El-Bedawi A (2013) Drug-Related Hospital Visits and Admissions Associated with Laboratory or Physiologic Abnormalities—A Systematic-Review. PLoS ONE 8(6): e66803. doi:10.1371/journal.pone.0066803

Editor: Giuseppe Biondi-Zoccai, Sapienza University of Rome, Italy

Received November 10, 2012; Accepted May 15, 2013; Published June 27, 2013

Copyright: © 2013 Wilbur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The research was funded by a Qatar University student grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: kwilbur@qu.edu.qa
attributed to medication may be generally grouped within the broader context of assignment of ADR-associated DRVs, but their differentiation is important as distinct preventative measures may be considered [15].

Our study objective is to estimate what proportion of total DRVs are associated with laboratory or physiologic abnormalities and therefore potentially be prevented with augmented monitoring systems.

Methods

Searching

Three authors (KW, HH, AE) independently performed comprehensive searches in relevant health care databases: PubMed (1966-November Week 1 2011); Embase (1947-November Week 1 2011); Cochrane Central Register of Controlled Trials (March 1996 to 3rd Quarter 2011); Web of Science® (1900-November Week 1 2011); Scopus® (1996-November Week 1 2011); Science Direct® (1995-November Week 1 2011); and Latin American Caribbean Health Sciences Literature (1982–2011). Predetermined search terms included key words and phrases: “medication-related” or “drug-related”; “hospitalization”; “emergency department”; “visit” or “admission”. No language restrictions were applied. Search strategies were modified to accommodate the controlled vocabulary in these databases. References of retrieved articles were also hand-searched.

Abstracts of unpublished studies were identified by electronic searching of available databases: International Pharmaceutical Abstracts (1970-November Week 1, 2011) and Cumulative Index to Nursing and Allied Health Literature (1982-November week 1, 2011) as well as by hand-searching International Society of Pharmaceutical Outcomes Research, American College of Clinical Pharmacy, American Society of Health-System Pharmacists, Canadian Society of Hospital Pharmacy, European Society of Clinical Pharmacy conference proceedings. Pre-determined search terms were also applied to a general internet search using Google Scholar.

Study Selection and Characteristics

The titles and abstracts of articles identified by the search were screened for potential relevance. The duplicate article titles identified among the searches by the three authors were eliminated. Full-text of potentially relevant studies were retrieved and considered eligible for inclusion according to pre-determined selection criteria: 1) evaluation of drug-related presentation to an ED for care; and/or 2) evaluation of a drug-related admission to an inpatient setting; and 3) data reported in sufficient detail to identify drug-related ED visit or hospitalization associated with abnormal laboratory value/s or physiologic findings. Adverse physiologic events were identified according to study documentation of specific clinical findings: 1) elevated or decreased systolic blood pressure; 2) elevated or decreased heart rate; 3) elevated or decreased respiratory rate; 4) elevated temperature or; 5) overt bleeding event [15]. Studies of both adult and pediatric populations were included. Articles were excluded if they: 1) described ED visit or hospitalization due to illicit drug use or abuse or intentional overdose; 2) described drug-related visits to ambulatory or primary care settings; 3) described inpatient detection of drug-related problems; or 4) were narrative reviews or commentaries. Disagreements about inclusion were resolved in author consensus meetings.

Validity Assessment

The three authors independently assessed selected relevant articles according to the Strengthening the reporting of observational studies in epidemiology (STROBE) guide as applicable according to the studies’ methodology to guide data extraction [16]. The methods for identification and criteria for subsequent characterization of a drug-related cause for emergency visit or hospitalization; methods used to establish causal relationship between the medication and observed outcome; tools for assessing the preventability and the severity of the DRV were also assessed to determine study quality and were graded as yes, no, unclear, or not reported [17].

Data Abstraction

A standardized data extraction form was developed according to the studies’ variables of interest: year of publication; country of original; study setting, design; population; methods of data collection and profession of data collectors; means for categorizing potential drug-related visits and admissions; means for characterizing preventability of drug-related visits and admissions; number and nature of drug-related laboratory or physiologic abnormalities; and finally the medications associated with these. Final inclusion and exclusion decisions were then made by author consensus.

Qualitative Data Synthesis

The methodological heterogeneity across studies including identification and classification of DRPs precluded rigorous quantitative assessment (meta-analysis) and so the study results are described and evaluated qualitatively.

Results

Flow of Included Studies

The initial literature search yielded a total of 1,524 articles (Figure 1). After reviewing the titles and abstracts, 1,099 articles were excluded. These articles included duplicate titles (270), description of DRVs due to illicit drug use or abuse (256); reports of DRVs to ambulatory or primary care settings (187); research of inpatient detection of DRPs (114); or were narrative reviews, commentaries, editorials or letters (272). Four-hundred and twenty-five studies remained for full text review, but despite an English abstract, 14 were not available in English and 408 did not provide sufficient details to determine laboratory or physiologic abnormalities among the DRVs or admissions recorded. We included 30 articles in the review.

Study Characteristics

Study characteristics of the included articles are described in Table 1 [18–47]. A total number of 98,138,737 patient admissions were evaluated in the included studies. The majority was conducted among adult populations only and 10 specifically assessed geriatric-DRVs. Only 1 study was performed in pediatrics. The studies were conducted in health care settings throughout the world, but predominantly in Europe, and spanned over a wide range of evaluation time periods (2 weeks to 26 years). Seven studies examined drug-related ED visits alone, while 13 involved drug-related hospital admission to particular patient care units, usually internal medicine or related sub-specialty ward/s. Half of the studies employed prospective methodologies that included patient interview complemented by medical chart review. Three reports estimated DRVs according to retrospective study of national hospitalization databases.
Adverse drug reaction-associated DRVs was the predominant DRP evaluated (25/30) and combined with drug interaction-associated DRVs in 4 of these studies. Five studies included all DRPs when determining DRV etiology (Table 1). The WHO definition for ADR (14/25) or a comparable one (5/25) was used in the studies evaluating ADR-associated DRVs, but 2 did not explicitly offer an ADR description. The 3 studies using patient registries screened ADR-related DRVs according to recorded ICD-9CM coding systems. All studies evaluating drug interactions described their tertiary and secondary resources. When investigators considered all DRPs in determining DRVs (5/30), recognized categories outlined by Hepler and Strand or Hallas were employed [1], [48].

Nearly three quarters of the studies (25/30) mentioned a causality assessment of the suspected DRV, of which the Naranjo algorithm (9/30) and WHO algorithm (8/30) were the most frequently used tools. Few studies (10/30) performed an assessment of the severity of patient outcome resulting from DRVs and only half of these descriptions were derived from a cited reference. Eighteen studies did not report assessment of the preventability of the DRVs they identified but 12 used recognized tools, such as Hallas, Schumock and Thornton, and Gurwitz [48–50].

Thirteen studies reported that a clinician was involved in the initial patient data screening and identification of the DRVs and followed a secondary process of patient data evaluation to subsequently validate the classification [21,24,25,29,30,32–34,41–45]. In these reports, the study team was often multidisciplinary, and may have included physicians, pharmacists, or nurses. Seven additional studies also described initial clinician determination of DRVs, but did not report additional independent case adjudication [18,19,26,27,36,37,40]. Ten studies did not provide information about who identified the DRVs [20,22,23,28,31,35,38,39,46,47].

Data Synthesis

The mean (range) prevalence of DRVs found in these studies was 15.4% (0.44%–66.7%) (Figure 2). In our pooled analysis, the overall mean (range) proportion of these DRVs that could be attributed to insufficient patient medication monitoring was 50.7% (6.8%–100%) (Figure 3). We could identify laboratory abnormalities in a mean of 29.4% (range 4.3%–78.1%) and findings of adverse physiologic events in a mean of 23.3% (range 2.5%–53.3%) contributing to the overall rate of DRVs as recorded by the investigators. Even if studies sampling subjects from national or hospital databases are censored and the evaluated patient admissions in our analysis drops considerably from 98,138,737 to 29,570, mean estimated prevalence of overall DRVs, laboratory- and physiologic-related DRVs are not considerably altered (16.5%, 31.9%, and 24.5%, respectively). There is also no appreciable difference when retrospective (32.8%) and prospective
| Study      | Country | Participants | DRV | Study Design | Study Method | Duration           | DRPs Evaluated | DRVs attributed to DRPs, n (%) | Laboratory- and/or Physiologic-Related DRV, n (%) |
|------------|---------|--------------|-----|--------------|--------------|--------------------|----------------|---------------------------------|--------------------------------------------|
| Foisy 2000 | Canada  | Adult with HIV | Hospital | R     | CR           | 1 Y pre- and post-initiation of HAART | ADR, DI associated with HAART | 4.4% (19/436) pre-HAART therapy, 7.7% (25/332) post-HAART therapy | 89% (17/19) laboratory pre-therapy, 64% (16/25) laboratory post-therapy |
| Green 2000 | UK      | Adult         | ED  | P     | CR & PI     | Unclear           | ADR            | 7.5% (15/200)                  | 33% (5/15) laboratory 20% (3/15) physiologic |
| Chan 2001  | Australia | Adult ≥75 Y   | ED  | P     | CR & PI     | 2 M               | All DRPs        | 30.4% (73/241)                | 11% (8/73) laboratory 37% (27/73) physiologic |
| Hohl 2001  | Canada   | Adult >65 Y   | ED  | P     | CR           | 1 Y               | ADR, DI         | 10.6% (30/282)                | 23.3% (7/30) laboratory 16.6% (7/30) physiologic |
| Wasserfallen 2001 | Switzerland | Adult | ED  | P     | CR & PI     | 6 M               | ADR            | 7.2% (229/3,195)              | 10.9% (25/229) laboratory 44.5% (102/229) physiologic |
| McDonnell 2002 | US | Adult | Hospital | R     | CR           | 11 M              | ADR            | 62.3% (96/154) *preventable ADR | 19.5% (16/82) laboratory 15.8% (13/82) physiologic |
| Mjörndal 2002 | Sweden | Adult | IMD, Cardio | P     | CR & PI     | 9 M               | ADR            | 18.1% (82/452)                | 18.1% (48/265) laboratory 42% (11/265) physiologic |
| Howard 2003 | UK      | Adult         | Hospital | P     | CR & PI     | 6 M               | All DRP         | 6.5% (265/4,093)              | 18.6% (19/102) laboratory 2.9% (3/102) physiologic |
| Juntti-Patinen 2006 | Finland | Adult >60 Y | ED  | P     | CR & PI     | 6 M               | ADR            | 1.4% (102/7,113)             | 33.3% (6/18) laboratory 27.7% (5/18) physiologic |
| Von Euler 2006 | Sweden | Adult | IMD  | R     | CR           | 3 W               | ADR            | 11% (18/168)                  | 18.8% (67/1,967) laboratory 31.2% (5/16) physiologic |
| Patel 2007  | UK      | Adult         | Hospital | R     | National database | 7 Y       | ADR            | 0.5% (68,971/88,822,005)     | 8.3% (5,752/68,971) laboratory 4.7% (21/82) physiologic |
| Rivkin 2007 | US      | Adult         | MICU | P     | CR & PI     | 6 M               | ADR            | 7.5% (21/281)                 | 19.4% (4/21) laboratory 4.7% (1/21) physiologic |
| Alexapoulou 2008 | Greece | Adult         | IMD  | P     | CR & PI     | 6 M               | ADR            | 12.7% (70/548)                | 42.8% (30/70) laboratory 40% (28/70) physiologic |
| Franchesci 2008 | Italy | Adult ≥65 Y   | Hospital | P     | CR & PI     | 13 M              | ADR            | 5.8% (102/1,756)             | 2.7% (13/102) laboratory 2.7% (13/102) physiologic |
| Hopf 2008   | Scotland | Adult         | Hospital | P     | CR & PI     | 15 D              | ADR            | 1.3% (30/2,371)              | 30% (9/30) laboratory 40% (12/30) physiologic |
| Bravar 2009 | Slovenia | Adult         | ED, IMD specialty R depts | CR | CR        | 1 Y               | ADR            | 5.8% (30/520)                | 46.7% (14/30) laboratory 53.3% (16/30) physiologic |
| Rogers 2009 | UK      | Adult ≥65 Y   | IMD  | P     | CR & PI     | 3 × 1 M           | All            | 5.4% (26/485) and 61.5% (16/26) considered preventable | 31.25% (5/16) laboratory 37.5% (6/16) physiologic |
| Wawruch 2009 | Slovakia | Adult ≥65 Y   | IMD  | R     | CR           | 16 M              | ADR            | 7.8% (47/600)                | 23.4% (11/47) laboratory 40.4% (19/47) physiologic |
| Davies 2010 | UK      | Adult         | Hospital | R     | CR           | Unclear           | ADR            | 16.9% (73/403)               | 35.6% (26/73) laboratory 20.5% (15/73) physiologic |
| Fokter 2010 | Slovenia | Adult         | Hospital | R     | CR           | 1 Y               | DI, ADR         | 51.4% (166/323) DI 6.2% (20/323) ADR | 7.4% (6/166+8/20) laboratory 21.3% (28/166+12/20) physiologic |
| Study        | Country                  | Participants | DRV     | Design | Method | Duration | DRPs Evaluated | DRV attributed to DRPs, n (%) | Laboratory- and/or Physiologic-Related DRV, n (%) |
|-------------|--------------------------|--------------|---------|--------|--------|----------|----------------|------------------------------|----------------------------------|
| Hartholt 2010 | The Netherlands          | Adult >60 Y  | Hospital | R      | National database | 26 Y   | ADR            | 247,638 DRV total admissions not reported | 4.5% (10,641/247,638) laboratory 2.5% (6,206/247,638) physiologic |
| Rodenburg 2010 | The Netherlands          | Adult        | Hospital | R      | National database | 5 Y    | ADR            | 0.44% 41,260/9,287,162 | 15.5% (6,405/41,260) laboratory 13.6% (5,632/41,260) physiologic |
| Somers 2010   | Belgium                  | Elderly Adult| Geriatric ward | P    | CR & PI | 3 × 1 M | All            | 21% (23/110) | 20% (5/25) laboratory 28% (7/25) physiologic |
| Gallagher 2011 | UK                      | Pediatric    | ED, Hospital | P    | CR & PI | 2 W    | ADR            | 1.1% ED (3/847) 3.2% Hospital (27/847) | 44.4% (12/27) laboratory 3.7% (1/27) physiologic |
| Hellstrom 2011 | Sweden                  | Adult        | ED, IMD   | P      | CR & PI | 4 × 1 M | All DRPs      | (8/86) 40.9% | 37.5% (3/8) laboratory 37.5% (3/8) physiologic |
| Hofer-Dueckelmann 2011 | Germany                | Adult        | Cardio, Nephro, GI wards | CR & PI | 2 × 3 M | ADR            | (7.6% (242/3,190) | 7.8% (189/242) laboratory 7.8% (19/242) physiologic |
| Marcum 2011   | US                      | Adult ≥65 Y  | Hospital  | R      | CR    | 2 Y    | ADR            | 10% (68/678) | 29.4% (20/68) laboratory 25% (17/68) physiologic |
| Miranda 2011  | Brazil                  | Adult        | Oncology ward | R    | CR    | 8 M    | ADR, DI       | 13.1% (39/298) (33 ADR+6 DI) | 51.3% (20/39) laboratory 15.4% (6/39) physiologic |
| Noize 2011    | France                  | Adult        | IMD specialty depts | R    | CR    | 1 Y    | ADR (hyperkalemia) | 66.7% (112/168) |  |
| Varallo 2011  | Brazil                  | Adult >60 Y  | IMD      | P      | CR & PI | 5 M    | ADR            | 42.9% (60/140) | 8.3% (5/60) laboratory+physiologic |

ADR: adverse drug reaction; Cardio: cardiology; CR: chart review; Depts: departments; DRP: drug-related problem; DRV: drug-related visit; ED: emergency department; GI: gastrointestinal; HAART: highly active antiretroviral therapy; IMD: internal medicine; M: months; MICU: medical intensive care unit; Nephro: nephrology; P: prospective; PI: patient interview; R: retrospective; Y: years.

doi:10.1371/journal.pone.0066803.t001
(49.3%) studies are compared (Figure 4). When studies evaluating laboratory- and physiologic-related DRV to the ED department alone are compared to those only evaluating DRVs leading to hospital admission, the incidence is somewhat higher (49.3% vs 44.9%, respectively, Figure 5). Observed mean estimates of the incidence of laboratory- and physiologic-related DRVs varied according to length of evaluation reported by (<3 months 55.8%; 3–6 months 46.9%; 7–11 months, 57.9%; 1–5 years, 43.2%; and >5 years, 7.67%). When all DRP-related admissions are considered, the overall incidence of DRV is 53.2% compared to those studies evaluating only one DRP (ADRs, 48.3%) or two DRPs (ADRs and DIs, 60.1%) contributing to the DRV (Figure 6).

The most common laboratory-related DRVs were abnormalities in electrolytes (hyponatremia, hyper- and hypokalemia); blood dyscrasias (anemia, neutropenia); metabolic disturbances (hyperand hypoglycemia); and acute renal failure. Overt bleeding events (upper gastrointestinal bleeding, melena), hypotension and bradycardia were most frequently identified adverse physiologic events. Laboratory-associated DRVs were most linked to anticoagulant, antiplatelet, diabetes and immunosuppressant drugs, whereby cardiovascular and NSAID analgesic therapeutic categories were ranked highest for physiologic-associated DRVs. Culprit drug therapy identified by investigators included loop diuretics, ACE inhibitors, aspirin, warfarin, thiazide diuretics, digoxin, beta blockers, sulphonylureas, and corticosteroids. Laboratory assessment detected values outside recognized therapeutic ranges in patients anticoagulated (elevated INR, n = 64), receiving digoxin (n = 29), antiepileptic therapy (n = 23) and lithium (n = 5).

Discussion

This is the first systematic review of DRVs attributed to complications associated with abnormalities in laboratory values and adverse physiologic events. Prior work has also sought to quantify the prevalence of monitoring problems contributing to preventable hospital admissions and found median (range) rate of 22.2% (0–31.3%) across 5 papers [6]. In that study, the characterization of a “monitoring problem” was not overtly defined and presumably relied upon the interpretation of the original authors of the studies in question. Our review is more broad, in that we made an independent determination of laboratory or physiologic abnormalities according to the detailed DRV data reported by the investigators and considered studies which did not necessarily ascribe preventability to its identified DRVs.

We found that on average half of identified DRVs were associated with patient morbidity that researchers linked with an irregularity in a monitored parameter. Apparent evidence of these laboratory and physiologic abnormalities contributing to DRV is consistently reported across the studies we included in our analysis, but incidences are highly variable (4.3%–100%). The broad range is not dissimilar to study findings of DRV prevalence in general.
and it is known that methodological factors impact observed rates [51]. Our review similarly includes diverse study settings and populations with considerations of all hospital admissions as well as acute admissions to specific patient care areas or ED visits alone. Just as identified by Leendertse et al, we too found that medical chart screening yielded higher prevalence of DRVs and subsequent linkage to laboratory or physiologic abnormality than in our three included studies of retrospective review of databases [51]. However, retrospective chart review usually reported only slightly higher rates than the prospective chart reviews in our study. Prospective data collection complemented by patient interview may yield more conservative estimates as the subject is available to inform or refute existence of a DRV whereas appropriate characterization validation is unavailable in retrospective studies.

We examined investigator methods for detecting a DRV, how causality was established between the untoward event and offending drug therapy, as well as its preventability and severity. Despite global interest in comprehensive evaluation of DRVs that may be associated with any category of DRPs, a valid assessment tool is lacking. Conversely, a number do exist specifically for identification of suspected ADRs experienced by patients and were employed by most researchers of the studies we included. We found most studies applied a recognized causality assessment, but few reported the severity or estimated preventability of the DRVs. The ability to classify DRVs by preventability provides a mechanism for clinicians to implement specific interventions and subsequently evaluate their impact on patients and health systems. Having said this, our review inherently emphasizes DRVs associated with patient parameters whereby augmented monitoring strategies could identify and address potential concerns before the patient was faced with an ED visit or hospital admission. The validity and reliability of DRV detection as reported in the included studies is weak. The majority seemed to rely on a single initial screening phase without further independent review. Professional characteristics of the reviewer must also be considered when exploring reliability in DRV detection. It has been previously demonstrated that physicians overlook DRPs as a cause for emergency department visits [52],[53].

Adverse drug reactions were the predominant DRP investigated in our included studies. The ADR definition most often employed was that of the WHO and defined as “any response to a drug which is noxious and unintended occurring at human doses for prophylaxis, diagnosis and therapy” [54]. A laboratory or physiologic abnormality may arise from an exaggerated, but unintended response (e.g. bradycardia with beta-blockers) or an unexpected adverse reaction unrelated to conventional pharmacology (e.g. agranulocytosis with chlorpromazine). It is worthwhile for future DRVs studies to incorporate alternate DRPs as sources of laboratory and physiologic abnormalities as these can occur from problems with medication adherence (e.g. low INR reported in anticoagulated patient admitted for stroke); drug interaction (e.g. subtherapeutic phenytoin value reported in patient receiving

![Figure 3. Laboratory and Physiologic-Abnormality Associated DRV, overall pooled mean incidence and 95% CI.](doi:10.1371/journal.pone.0066803.g003)
concomitant antibiotic and admitted with seizure); or inappropriate prescribing (e.g. increasing ACE inhibitor dose in the face of hyperkalemia) [55]. Efforts to ameliorate deficiencies in laboratory monitoring of specific drug therapies or of specific patients have been described with few successes. Suboptimal laboratory monitoring occurs under conditions when there is both failure to conduct indicated tests at baseline or at appropriate follow-up intervals and inadequate response when results are reported [56]. Patients’ prescribed therapy attributed to findings of inappropriate laboratory parameters contributing to DRVs in our included studies are medications already known to possess risks of organ-system toxicities or imbalances to electrolytes and metabolic factors. While monitoring plans have already been outlined for a number of these therapies, a host of practical implementation barriers have been identified such as unclear assignment of responsibility when multiple physicians are involved in care; lack of alerts/reminders; physician fatigue and inaction due to indiscriminant computer alters/reminders; and patient non-adherence to instructions, to name just a few [57–59]. Team-based and interdisciplinary approaches are needed to promote appropriate medication monitoring. As highly accessible qualified health care providers, pharmacists can assume shared responsibility with prescribers to ensure appropriate laboratory assessments are conducted and reviewed. When electronic clinical decision support is in place, pharmacists improve patient care and safety by reducing potentially inappropriate prescribed therapy [60]. Studies have also shown that such pharmacist-led laboratory alert prompting prescriber medication review can be cost-effective [61]. When such patient data are not readily available, it is reasonable to consider acquisition of relevant laboratory information or physiologic assessments mandatory as a required element for safe and responsible provision of therapy, not unlike determination of a patient’s drug allergy status prior to prescription processing and dispensing [62],[63].

Our review confirms that lack of adequate laboratory monitoring contributes to patient morbidity; however our evaluation of the occurrence of adverse physiologic events is a concept both not well defined and perhaps consequently not previously explored. Physical exam is a systematic process for investigating the body and its function. Physical assessment skills necessary for health professionals to conduct complete and accurate patient evaluations have largely remained in the domain of physicians, nurses, and even physiotherapists. Pharmacist roles and responsibilities to ensure the optimal outcomes from the use of medication are patient-centered and expanding in scope, which includes developing skills in percussion, palpation and auscultation [64],[65]. Combined with customary verbal patient information gathering and inspection skills, pharmacists are increasingly equipped to recognize adverse physiologic effects of drugs through vital sign assessment and other straightforward physical exams. Observation and measurement of abnormal vital signs can be early indicators of

![Figure 4. Laboratory and Physiologic-Abnormality Associated DRV According to Study Methodology, mean incidence and 95% CI. doi:10.1371/journal.pone.0066803.g004](image-url)
potential or actual DRPs and is an area of medication monitoring to be explored in study of DRV prevention.

A number of limitations to our review warrant discussion. Information for our analysis was derived from the published reports and we did not contact authors of screened studies for further data, which may diminish how representative our review is in the context of other available literature. Furthermore, yield from our search for any preliminary data (e.g. published conference proceedings) and non-English language sources was negligible, underscoring just some of the effects of publication bias which we did not attempt to estimate or overcome with corrective techniques (e.g. modeling, fail safe N). We did not explicitly use “adverse drug reaction” in our search strategy and although most of our included studies assessed this particular DRV etiology, it is possible we could have missed some evaluations of DRV due to this or any other singular and specifically described DRP.

There has been little definitive work regarding adverse physiologic events and in the past might be incorporated within the context of a medication ADRs. We defined these events according to one prior report that only encompassed abnormal vital signs to which we added episodes of major or minor bleeding. Our working definition likely underestimated the prevalence of physiologic adverse events. For example, a number of studies included in our review reported exacerbations of heart failure as a

Figure 5. Laboratory and Physiologic-Abnormality Associated DRV According to Patient Setting, mean incidence and 95% CI. doi:10.1371/journal.pone.0066803.g005
Figure 6. Laboratory and Physiologic-Abnormality Associated DRV According to Drug-Related Problem (DRP), mean incidence and 95% CI.
doi:10.1371/journal.pone.0066803.g006
DRV. If the accompanying documentation did not specifically refer to altered respiratory status (a vital sign), we did not characterize that patient’s DRV as an adverse physiologic event. It is possible that future interpretations may accommodate other patient outcomes easily screened through simple physical assessment or patient interview, such as altered level of consciousness or peripheral edema. Finally, little can be concluded from our review regarding the specific nature of DRVs in children as the majority of included study populations were adults.

Conclusions

This review demonstrates laboratory abnormalities and adverse physiologic events represent a large proportion of documented drug-related emergency room visits and hospital admissions.

References

1. Hepler CD, Strand LM (1990) Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 47:533–43.

2. Easton KL, Parsons BJ, Brien J (2004) Frequency and characteristics of hospital admissions associated with drug-related problems in pediatrics. Br J Clin Pharmacol 57:611–5.

3. Samoy MA, Zed PJ, Wilbur K, Balen RM, Abu-Laban RB, et al (2006) Drug-related hospitalizations in a tertiary care internal medicine service of a Canadian hospital: a prospective study. Pharmacotherapy 26:1578–86.

4. Zed PJ, Abu-Laban RB, Balen KM, Loewen PS, Holm CM, et al (2008) Incidence, severity, and preventability of medication-related visits to the emergency department: a prospective study. Can Med Assoc J 178:1563–69.

5. Singh H, Kumar BN, Sinha T, Dalhani N (2011) The incidence and nature of drug-related hospital admission: a 6-month observational study in a tertiary health care hospital. J Pharmacoepidemiol Drug Saf 11:63–72.

6. Howard RL, Avery AI, Slavenburg S, Royal S, Pipe G, et al (2006) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63:136–47.

7. Leendertse AJ, de Koning FHP, Goudswaard AN, Jonkhoff AR, van den Bogert MJCM, et al (2010) Adverse drug reactions related hospital admissions in persons aged 60 years and older. JAGS 59:1513–20.

8. Atiqi R, van Bommel E, Cleophas TJ, Zwinderman AH (2010) Prevalence of iatrogenic admissions to the Departments of Medicine/Cardiology/Pulmonology in a 1,250 bed general hospital. Int J Clin Pharm Ther 48:517–24.

9. Warle-van Herwaarden MF, Kramers C, Sturkenboom MC, van den Bemt PM, Stoker LJ (2008) Drug-related emergency room visits and hospital admissions associated with drug-related problems in pediatrics. Br J Clin Pharmacol 65:697–707.

10. Steinman MA, Handler SM, Gurwitz JH, Schiff GD, Covinsky KE (2011) Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 168:1890–96.

11. Leendertse AJ, de Koning FHP, Goudswaard AN, Jonkhoff AR, van den Bogert SC, et al (2011) Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomized, controlled, multicentre PHARM-study. BMC Health Serv Res 11:14.

12. Morrato EH, Newcomer JW, Allen RR, Valic RJ (2008) Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, populations-based study of Medicaid claims data. J Clin Psychiatri 69:316–22.

13. Tija T, Field TS, Garber LD, Donovan JL, Kanaan AO, et al (2010) Development and pilot testing of guidelines to monitor high-risk medications in the ambulatory setting. Am J Manag Care 16:489–96.

14. Tija J, Fischer SH, Rachel MA, Peterson D, Zhao Y, et al (2011) Baseline and follow-up of laboratory monitoring of cardiovascular medications. Ann Pharmacother 45:1077–84.

15. James K, Bellomo R, Poustie S, Story DA, Nicoll PL (2000) The epidemiology of major early adverse physiological events after surgery. Crit Care Resuscitation 2:108–13.

16. STROBE Statement. Strengthening the reporting of observational studies in epidemiology. Strobe checklist for cohort, case-control, and cross-sectional studies: Available: URL: http://www.strobe-statement.org/index.php?id=available-checklists. Accessed 2011 Nov 28.

17. Smyth RMD, Gargen E, Kirkham, Creswell L, Golder S, et al (2012) Adverse drug reactions in children: a systematic review. PLoS ONE 7:e24062. doi:10.1371/journal.pone.0024061.

18. Foisy M (2000) Hospitalization due to ADR and DI before and after HAART. Can J Infect Dis 11:193–201.

19. Green CF (2000) ADRS as a cause of admission to an acute medical assessment unit: a pilot study. J Clin Pharmacol Ther 25:355–61.

20. Chan M, Niven V, Vail JJ (2000) Adverse drug events ADEs as a cause of hospital admission in the elderly. Intern Med J 31:199–205.

21. Holm CM, Dankoff J, Coeconom A, Affalda M (2001) Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 38:666–71.

22. Wasserfallen JB, Livio F, Bucklin T, Tillet L, Yerisin B, et al (2001) Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med 12:442–7.

23. McDonnell PJ, Jacobs MK (2002) Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36:1331–6.

24. Mjonudal T, Boman MD, Hagg S, Backstrom M, Wiholm BE, et al (2002) Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 11:63–72.

25. Howard RL, Avery AJ, Howard PD, Partridge M (2003) Investigation into the reasons for preventable ADRS to a medical admissions unit: observational study. Qual Saf Health Care 12:280–5.

26. Juntti-Patinnen L, Kuitunen T, Pera P (2006) Drug-related visits to a district hospital emergency room. Bas Clin Pharmacol Toxic 90:212–7.

27. von Euler M, Ellasson E, Ohlen G, Bergman U (2006) Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization. Pharmacoepidemiol Drug Saf 15:179–84.

28. Patel H, Bell D, Molokhia M, Srishannuganathan J, Patel M, et al (2007) Trends in hospital admissions for ADRs in England: analysis of national hospital episode statistics 1998–2005. BMC Clin Pharmacol 7:9.

29. Rovik A (2007) Admissions to medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 64:1840–3.

30. Alexopoulos A, Dourakis SP, Mantzoukis D, Pitsiaritis T, Kandylì A, et al (2008) Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med 19:505–10.

31. Franchesci M (2008) Prevalence, clinical features and availability of ADRS as a cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 31:345–56.

32. Hopf Y, Watson M, Williams D (2008) Adverse drug reaction related admissions to a hospital in Scotland. Pharm World Sci 30:854–62.

33. Brvar M, Fokter N, Bunc M, Mozina M (2009) The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department speciality. BMC Clin Pharmacol 9:8. doi:10.1186/1472-6904-9-8.

34. Rogers S, Wilson D, Wan S, Griffin M, Rai G, et al (2009) Medication-related admissions in older people: a cross-sectional observational study. Drugs Aging 26:951–61.

35. Wawruch M, Zikavskas M, Wiołowa L, Kuzelova K, Kahlavova K, et al (2009) Adverse drug reactions related to hospital admissions in Slovak elderly patients. Arch Gerontol Geriatr 48:186–90.

36. Davies EG, Green CF, Moltrum DR, Rose PH, Pinnaduwage M (2010) Emergency re-admissions to hospital due to adverse drug reactions within 1 year of index admission. Br J Clin Pharmacol 70:749–55.

37. Fokter N (2010) Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wien Klin Wochenschr 122:81–8.

38. Hartzold KA, van der Velde N, Looman CW, Panneman MJ, van Beeck EF, et al (2010) Adverse drug reactions related hospital admissions in persons aged 60 years and over. The Netherlands 1981–2007: less rapid increase, different drugs. PLoS One 5:e13597.

39. Rodenburg EM, Stricker BH, Visser LE (2010) Sex-related differences in hospital admissions attributed to adverse drug reaction in the Netherlands. Br J Clin Pharmacol 71:95–104.

40. Somers A, Robays H, Vander Stichche R, van Maele G, Bogaert M, et al (2010) Contributions of drug-related problems to hospital admissions in elderly. J Nutr Health Aging 14:476–82.
41. Gallagher RM, Bird KA, Mason JR, Peak M, Williamson PR, et al (2011) Adverse drug reactions causing admission to a paediatric hospital: a pilot study. J Clin Pharm Ther 36:194–99.
42. Hellstrom LM, Bondesson A, Hoglund P, Millof P, Holmdahl L, et al (2011) Impact of the Lund Integrated Medicines Management (LIMM) model on medication appropriateness and drug-related hospital revisits. Eur J Clin Pharm 67:741–52.
43. Hofer-Dreuckelmann C, Prinz E, Beindl W, Szymanski J, Fellhofer G, et al (2011) ADRs associated with hospital admissions – elderly female patients are at higher risk. Int J Clin Pharmacol Ther 49:577–86.
44. Marcum ZA, Arman ME, Hanlon JT, Aspinall SL, Handler SM, et al (2011) Prevalence of unplanned hospitalizations caused by ADRs in veterans. J Am Geriatr Soc 60:34–41.
45. Miranda V, Fede A, Nobuo M, Ayres V, Giglio A, et al (2011) Adverse drug reactions and drug interaction as causes of hospital admission in oncology. J Pain Symptom Manage 42:342–53.
46. Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, et al (2011) Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Pharmacoepidemiol Drug Saf 20:747–53.
47. Varallo FR, Capucho HC, Planeta CS, Mastroianni PhdC (2011) Safety assessment of potentially inappropriate medications use in older people and the factors associated with hospital admission. J Pharm Pharmacut Sci 14:283–90.
48. Hallas J, Harvald B, Gram LF, Groshum E, Broen K, et al (1990) Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 228:83–90.
49. Shumock GT, Thornton JP (1992) Focusing on the preventability of adverse drug reactions. Hosp Pharm 27:538–Letters.
50. Gurvitz JH, Field TS, Harold LR, Rothchild J, Debelis K, et al (2003) Incidence and preventability of adverse drug events among elderly persons in the ambulatory setting. JAMA 289:1107–16.
51. Leendertse AJ, Visser D, Egberts ACG, van Den Berst PM (2010) The relationship between study characteristics and the prevalence of medication-related hospitalizations. A literature review and novel analysis. Drug Saf 33:233–44.
52. Ajdukovic M, Crook M, Angley C, Stupans I, Soulsby N, et al (2007) Pharmacist elicited medication histories in the Emergency Department: identifying patient groups at risk of medication misadventure. Pharm Pract 5:162–8.
53. Hohl CM, Zed PJ, Brobacher JR, Abou-Laban RR, Loewen PS, et al (2010) Do emergency physicians attribute drug-related emergency department visits to medication-related problems? Ann Emerg Med 55:493–502.
54. World Health Organization (1970) International drug monitoring—the role of the hospital. A WHO report. Drug Intell Clin Pharm 4:101–11.
55. von Mil JW, Westerlund LO, Hersberger KE, Schaefer MA (2004) Drug-related problem classification systems. Ann Pharmacother 38:859–67.
56. Raelb MA, Lyons EE, Chester EA, Bodily MA, Kelleher JA, et al (2005) Improving laboratory monitoring at initiation of drug therapy in ambulatory care. Arch Intern Med 165: 2993–2994.
57. Tija J, Fisher S, Raelb MA, Peterson D, Zhao Y, et al (2011) Baseline and follow-up of laboratory monitoring of cardiovascular medications. Ann Pharmacother 45:1077–84.
58. Goldman RE, Soran CS, Hayward GL, Simon SR (2010) Doctors’ perceptions of laboratory monitoring in office practice. J Eval Clin Pract 16:1136–41.
59. Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles MP, et al (2009) The effects of on-screen, point of care computer reminders on processes and outcomes of care. Cochrane Database of Syst Rev DOI:10.1002/14651858.CD001096.pub2.
60. Bhargava B, Carroll NM, Raelb MA, Chester EA, Korn EJ, et al (2011) Improving prescribing safety in patients with renal insufficiency in the ambulatory setting: the Drug Renal Alert Pharmacy (DRAI) Program. Pharmacotherapy 31: 346–56.
61. Smith DH, Feldstein AC, Perrin NA, Yang X, Rix MM, et al (2009) Improving laboratory monitoring of medications: an economic analysis alongside a clinical trial. Ann J Managed Care 15:281–9.
62. Leape LL, Bates DW, Cullen DJ, Cooper J, Demosco HJ, et al (1995) Systems analysis of adverse drug events. JAMA 274:33–43.
63. Jones TA, Como JA (2003) Assessment of medication errors that involved drug allergies at a university hospital. Pharmacotherapy 23:853–60.
64. Bolstad S, Trembetta DP, Longshore DS (2011) Pharmacist instruction of physical assessment for pharmacy students. Am J Pharm Educ 75: Article 29.
65. Barry AR, McCarthy L, Nelson CL, Pearson GJ (2012) An evaluation of teaching physical examination to pharmacists. Can Pharm J 145:174–79.